Der p 1 peptides for HDM allergy
Research type
Research Study
Full title
Immunological Validation of Der p 1 Peptides for the Treatment of House Dust Mite Allergy
IRAS ID
251822
Contact name
David Wraith
Contact email
Sponsor organisation
Research Governance Department
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
Allergic rhinitis and asthma affects ~23% and 10% of the population respectively in Europe and house dust mite allergy (HDM) drives the disease in the majority of patients. Allergic rhinitis and asthma costs the NHS over a billion pounds annually. Allergen Specific Immunotherapy (SIT) to HDM is a specialist treatment that involves giving regular injections of ‘whole’ mite allergen. The immune system converts the HDM allergen into smaller fragments called ‘peptides’ that helps develop tolerance and relief from allergy. SIT is, however, expensive and sometimes causes serious allergic reactions due to direct exposure of the immune system to ‘whole’ HDM allergen. Recent studies have shown that injecting small amounts of peptide from pollen or cat allergen into skin is an effective treatment for hay fever and cat allergy respectively. We have developed a novel laboratory system that identifies these peptides with precision after the allergen has been processed by the immune system. Using this novel method, we aim to validate HDM peptides (Der p 1) by carrying out experiments on blood samples taken from allergic and non-allergic individuals.
This study involves 3 groups of volunteers: (a) patients with HDM allergy (b) patients without HDM allergy but with allergy to other allergen/s (eg: pollen) and (c) non-allergic healthy controls. After obtaining an informed consent, we will obtain a clinical history, perform skin prick tests to aero-allergens and obtain a blood sample for characterisation of HDM allergy and for other relevant laboratory assays relating to validation of HDM peptides.REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
18/NW/0726
Date of REC Opinion
28 Oct 2018
REC opinion
Further Information Favourable Opinion